Welcome to Markets Desk, your midday read on what's moving the needle.
SpaceX's amended IPO filing is drawing serious attention on the Street. A single new provision reserves five percent of offering shares for employees, business partners, and what the filing calls friends — language that has deal watchers asking whether this quiet clause signals a merger of historic proportions quietly baked into the structure.
Staying with SpaceX, Starlink remains the crown jewel of that offering. It is the company's most profitable business unit, and how the IPO is priced will determine whether Starlink spins into its own trajectory or stays tethered to the broader SpaceX balance sheet. Institutional investors are watching the unit economics closely.
Shifting to pharma, the dividend debate between Bristol Myers Squibb and Pfizer is heating up among income-focused equity investors. Pfizer carries the higher forward yield, but Bristol Myers wins on most other fundamental measures — valuation, pipeline stability, and earnings coverage — making it the more defensible position for long-duration holders in this rate environment.
That's the tape. Markets Desk, signing off the floor.
